Art. -Nr.: HY-100614

Copy Link Print Information

AS1517499

48 Cited Publications

Kundenbewertung

Based on 48 publication(s) in Google Scholar

AS1517499 is a potent and brain-permeable STAT6 phosphorylation inhibitor with an IC₅₀ of 21 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.99%
CAS. Nr.: 919486-40-1
Formel: C₂₀H₂₀ClN₅O₂
Molecular Weight:397.86

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

AS1517499 Chemical Structure

CAS. Nr.: 919486-40-1

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (48)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

AS1517499 is a potent and brain-permeable STAT6 phosphorylation inhibitor with an IC₅₀ of 21 nM.

IC₅₀ & Target^[1]

STAT6

21 nM (IC₅₀)

Alle STAT Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
T-cell	IC₅₀	2.3 nM Compound: 2t, AS1517499	Effect on differentiation of C57BL/6 mouse T cells assessed as inhibition of IL4 production Effect on differentiation of C57BL/6 mouse T cells assessed as inhibition of IL4 production	[PMID: 17071093]

In Vitro

AS1517499 shows potent STAT6 inhibition with an IC₅₀ value of 21 nM, and also inhibits IL-4-induced Th2 differentiation of mouse spleen T cells with an IC₅₀ value of 2.3 nM and without influencing T-helper cell 1 (Th1) differentiation induced by IL-12. AS1517499 selectively inhibits Th2 differentiation without affecting Th1 differentiation^[1].
In cultured human BSM cells, IL-13 (100 ng/mL) causes a phosphorylation of STAT6 and an up-regulation of RhoA, a monomeric GTPase responsible for Ca²⁺ sensitization of smooth muscle contraction: both events are inhibited by co-incubation with AS1517499 (100 nM)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In BALB/c mice that are actively sensitized and repeatedly challenged with ovalbumin antigen, an increased IL-13 level in bronchoalveolar lavage fluids and a phosphorylation of STAT6 in bronchial tissues are observed after the last antigen challenge. These mice have an augmented BSM contractility to acetylcholine together with an up-regulation of RhoA in bronchial tissues. Intraperitoneal injections of AS1517499 (10 mg/kg) 1 hour before each ovalbumin exposure inhibits both the antigen-induced up-regulation of RhoA and BSM hyperresponsiveness, almost completely^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 919486-40-1
Appearance Solid
Molecular Weight 397.86
Formel C₂₀H₂₀ClN₅O₂
Color White to light brown
SMILES

O=C(C1=CN=C(NCCC2=CC=C(O)C(Cl)=C2)N=C1NCC3=CC=CC=C3)N
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (48)

All Flow CytometryRT-PCRCell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Cancer Cell

CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases. [Abstract]

2025 Jul 29:S1535-6108(25)00313-7. PMID: 40780215

AS1517499 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 29:S1535-6108(25)00313-7. [Abstract]

CHI3L3 expression in neutrophils treated with DKK1 protein and/or AS1517499 (p-STAT6 inhibitor, 1 μM; 24-48 h) was detected by flow cytometry.
Cancer Cell

Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. [Abstract]

2025 Feb 10;43(2):269-291.e19. PMID: 39933899
Immunity

Activating an interleukin 4-FLT3-STAT6 axis in multipotent progenitors restores lymphopoiesis in inflammation and aging. [Abstract]

2026 May 29:S1074-7613(26)00180-9. PMID: 42214327
Cell Mol Immunol

Serine metabolism orchestrates macrophage polarization by regulating the IGF1-p38 axis. [Abstract]

2022 Nov;19(11):1263-1278. PMID: 36180780
Nat Commun

Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma. [Abstract]

2024 Jun 21;15(1):5292. PMID: 38906855

AS1517499 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 21;15(1):5292. [Abstract]

Representative heatmaps for cell viability using MHH-ES-1 cells treated with indicated doses of compounds (AS1517499 (1-10 μM), SN-38 (3-30 μM)) for 2 days.

AS1517499 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 21;15(1):5292. [Abstract]

IB analysis of WCL from MHH-ES-1 cells treated with indicated compounds for 24 h. AS1517499, 5 μM; SN-38, 1 μM; etoposide, 10 μM.
Cell Death Differ

PP2Acα promotes macrophage accumulation and activation to exacerbate tubular cell death and kidney fibrosis through activating Rap1 and TNFα production. [Abstract]

2021 Sep;28(9):2728-2744. PMID: 33934104
Acta Pharm Sin B

The suppression of cervical cancer ferroptosis by macrophages: The attenuation of ALOX15 in cancer cells by macrophages-derived exosomes. [Abstract]

2023 Jun;13(6):2645-2662. PMID: 37425043
Compos B Eng

2023 Jan.
Adv Sci (Weinh)

TGM2 Aggravates Acute Pancreatitis by Impairing Macrophage Efferocytosis Through Inhibition of the STAT6-GAS6 Axis. [Abstract]

2026 Apr;13(24):e20739. PMID: 41703992
Theranostics

Cancer-associated fibroblast-derived periostin promotes papillary thyroid tumor growth through integrin-FAK-STAT3 signaling. [Abstract]

2024 May 13;14(7):3014-3028. PMID: 38773979

AS1517499 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 May 13;14(7):3014-3028. [Abstract]

AS1517499 (500 nM; 30 min) efficiently blocked IL-4-induced CAF activation and upregulation of POSTN in CAFs.

AS1517499 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 May 13;14(7):3014-3028. [Abstract]

AS1517499 (500 nM; 30 min) efficiently blocked IL-4-induced CAF activation and upregulation of POSTN in CAFs.
Theranostics

Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis. [Abstract]

2021 Jan 1;11(3):1192-1206. PMID: 33391530
Allergy

Club Cells in Nasal Epithelial Repair: Insights From an IL-13-Induced Inflammatory Model. [Abstract]

2025 Oct 22. PMID: 41123053
Redox Biol

IL-13 facilitates ferroptotic death in asthmatic epithelial cells via SOCS1-mediated ubiquitinated degradation of SLC7A11. [Abstract]

2024 May:71:103100. PMID: 38484644
J Exp Med

Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice. [Abstract]

2018 Aug 6;215(8):2175-2195. PMID: 29970474
Cell Death Dis

SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance. [Abstract]

2026 Jan 3. PMID: 41484064
Genes Dis

2026 Jan 20.
Cell Commun Signal

T cell receptor associated transmembrane adaptor 1 (TRAT1) modulates human Th17 and Treg responses via PI3-kinase and STAT dependent mechanisms. [Abstract]

2025 Oct 10;23(1):431. PMID: 41074026
Dev Cell

Stress-induced pro-inflammatory glioblastoma stem cells secrete TNFAIP6 to enhance tumor growth and induce suppressive macrophages. [Abstract]

2025 May 15:S1534-5807(25)00287-4. PMID: 40403724
Cancer Immunol Res

Blocking P2X7-Mediated Macrophage Polarization Overcomes Treatment Resistance in Lung Cancer. [Abstract]

2020 Nov;8(11):1426-1439. PMID: 32933967
Cell Rep

Tonic type 2 immunity is a critical tissue checkpoint controlling autoimmunity in the skin. [Abstract]

2024 Jun 18;43(7):114364. PMID: 38900635
Allergol Int

2026 Feb 17.
Ecotoxicol Environ Saf

Involvement of M2 macrophages polarization in PM2.5-induced COPD by upregulating MMP12 via IL4/STAT6 pathway. [Abstract]

2024 Aug 1:283:116793. PMID: 39094453
Cell Biol Toxicol

The mtDNA-STING pathway plays an important role in both navitoclax- and S63845-induced autophagy and enhances cell death. [Abstract]

2023 Dec;39(6):2821-2839. PMID: 37002446
Front Immunol

Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands+ Macrophages via Activating IL-4/STAT6/PD-L2 Signaling. [Abstract]

2021 Jul 5;12:683249. PMID: 34290705
Biochem Pharmacol

Dual inhibition of EGR1/STAT3 transcriptional hubs suppresses macrophage-driven liver fibrosis: A multi-omics-guided drug repurposing strategy. [Abstract]

2025 Oct:240:117120. PMID: 40623460
Inflamm Res

The RNA-binding protein KSRP reduces asthma-like characteristics in a murine model. [Abstract]

2025 Mar 17;74(1):54. PMID: 40095032
Inflamm Res

Alpha-galactosylceramide pre-treatment attenuates clinical symptoms of LPS-induced acute neuroinflammation by converting pathogenic iNKT cells to anti-inflammatory iNKT10 cells in the brain. [Abstract]

2024 Sep;73(9):1511-1527. PMID: 39028491
CNS Neurosci Ther

IL-4-JAK1-STAT6 Pathway Mediates Electroacupuncture's Effect on Microglial M2 Polarization to Treat Inflammatory Bowel Disease With Comorbid Depression. [Abstract]

2025 Aug;31(8):e70572. PMID: 40823702
Respir Res

IL-4-induced caveolin-1-containing lipid rafts aggregation contributes to MUC5AC synthesis in bronchial epithelial cells. [Abstract]

2017 Sep 20;18(1):174. PMID: 28931396
Int J Mol Sci

HSD3B1 Expression Is Upregulated by Interleukin 4 in HT-29 Colon Cancer Cells via Multiple Signaling Pathways. [Abstract]

2022 Nov 5;23(21):13572. PMID: 36362361
Int Immunopharmacol

Microbial metabolite tigloside alleviates osteoarthritis by repolarizing macrophages from M1 to M2 phenotype through Trafd1 destabilization and Trafd1-mediated NF-κB/STAT6 signaling pathways. [Abstract]

2026 Jan 1;168(Pt 1):115747. PMID: 41192114
Int Immunopharmacol

Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation. [Abstract]

2024 Sep 27;142(Pt B):113258. PMID: 39340991
Eur J Pharmacol

Loureirin B protects against cerebral ischemia/reperfusion injury through modulating M1/M2 microglial polarization via STAT6 / NF-kappaB signaling pathway. [Abstract]

2023 Aug 15:953:175860. PMID: 37331681
Molecules

Pulsatilla Saponins Inhibit Experimental Lung Metastasis of Melanoma via Targeting STAT6-Mediated M2 Macrophages Polarization. [Abstract]

2023 Apr 24;28(9):3682. PMID: 37175092
J Cell Mol Med

MCTR1 enhances the resolution of lipopolysaccharide-induced lung injury through STAT6-mediated resident M2 alveolar macrophage polarization in mice. [Abstract]

2020 Sep;24(17):9646-9657. PMID: 32757380
Sci Rep

Autocrine Production of Interleukin-34 Promotes the Development of Endometriosis through CSF1R/JAK3/STAT6 signaling. [Abstract]

2019 Nov 14;9(1):16781. PMID: 31727934
Food Sci Nutr

Lycium barbarum Polysaccharide Alleviates Renal Damage in Mouse Sepsis by Regulating M1/M2 Macrophage Polarization. [Abstract]

2026 Feb 15;14(2):e71561. PMID: 41700132
Food Sci Nutr

Octanoic Acid-Rich Enteral Nutrition Regulates Intestinal M1/M2 Macrophage Polarization via the PPARγ/STAT-1/STAT-6 Pathway to Alleviate Inflammatory Bowel Disease. [Abstract]

2025 Nov 17;13(11):e71234. PMID: 41256230
Cell Signal

CD137 signaling induces macrophage M2 polarization in atherosclerosis through STAT6/PPARδ pathway. [Abstract]

2020 Aug;72:109628. PMID: 32247042
Am J Physiol Lung Cell Mol Physiol

IL-4/IL-13 upregulates Sonic hedgehog expression to induce allergic airway epithelial remodeling. [Abstract]

2020 May 1;318(5):L888-L899. PMID: 32130032
J Immunol

The Anti-Inflammatory Immune Response in Early Trichinella spiralis Intestinal Infection Depends on Serine Protease Inhibitor-Mediated Alternative Activation of Macrophages. [Abstract]

2021 Mar 1;206(5):963-977. PMID: 33495238
J Immunol

IL-4 Treatment Mitigates Experimental Cerebral Malaria by Reducing Parasitemia, Dampening Inflammation, and Lessening the Cytotoxicity of T Cells. [Abstract]

2021 Jan 1;206(1):118-131. PMID: 33239419
Front Oncol

STAT6 Upregulates NRP1 Expression in Endothelial Cells and Promotes Angiogenesis. [Abstract]

2022 May 5;12:823377. PMID: 35600336
Allergy Asthma Clin Immunol

The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway. [Abstract]

2022 Feb 17;18(1):12. PMID: 35177102
Biochem Biophys Rep

Targeting STAT6 to mitigate sepsis-induced muscle atrophy and weakness: Modulation of mitochondrial dysfunction, ferroptosis, and CHI3L1-Mediated satellite cell loss. [Abstract]

2023 Dec 16:37:101608. PMID: 38188367
Iran J Immunol

JAK/STAT Signaling Pathway Mediates Anti-Tumor Immunity of CD8+ T Cells in Renal Cancer. [Abstract]

2024 Sep 25;21(3). PMID: 39319693
Patent

US20240307497A1.
Research Square Preprint

2022 Feb.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 35 mg/mL (87.97 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5134 mL

12.5672 mL

25.1345 mL

5 mM

0.5027 mL

2.5134 mL

5.0269 mL

10 mM

0.2513 mL

1.2567 mL

2.5134 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 12.5 mg/mL (31.42 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

Normal human BSM cells (hBSMCs) are maintained in SmBM medium supplemented with 5% fetal bovine serum, 0.5 ng/mL human epidermal growth factor (hEGF), 5 μg/mL insulin, 2 ng/mL human fibroblast growth factor-basic (hFGF-b), 50 μg/mL gentamicin, and 50 ng/mL amphotericin B. Cells are maintained at 37°C in a humidified atmosphere (5% CO₂), fed every 48 to 72 hours, and passaged when cells reached 90 to 95% confluence. Then the hBSMCs (passages 7-9) are seeded in 6-well plates and 8-well chamber slides at a density of 3,500 cells/cm2 and, when 80 to 85% confluence observed, cells are cultured without serum for 24 hours before addition of recombin is ant human IL-13. AS1517499 (100 nM) or its vehicle (0.3% DMSO) is treated 30 minutes before the addition of IL-13 (100 ng/mL). In some experiments, AS1517499 is treated 0 (co-incubation), 3, or 12 hours after the addition of IL-13. In another series of experiments, a selective Rho-kinase inhibitor Y-27632 (1 μM) or its vehicle (0.3% DMSO) is also applied 15 minutes before the IL-13 application. At the indicated time after the IL-13 treatment, cells are washed with PBS, immediately collected, and disrupted with 1× SDS sample buffer (250 μL/well), and used for Western blot analyses^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
Male BALB/c mice are used. Preparation of a murine model of allergic bronchial asthma, which has an in vivo AHR, is performed. In brief, BALB/c mice (8 wk of age) are actively sensitized by intraperitoneal injections of 8 μg ovalbumin (OVA) with 2 mg Imject Alum on Day 0 and Day 5. The sensitized mice are challenged with aerosolized OVA-saline solution (5 mg/mL) for 30 minutes on Days 12, 16, and 20. A control group of mice received the same immunization procedure but inhaled saline aerosol instead of OVA challenge. The aerosol is generated with an ultrasonic nebulizer and introduced to a Plexiglas chamber box (130×200 mm, 100 mm height) in which the mice are placed. Animals also received intraperitoneal injection with AS1517499 (1 or 10 mg/kg/d; dissolved in 20% DMSO in saline) or its vehicle 1 hour before each antigen inhalation (Days 12, 16, and 20). Twenty-four hours after the last OVA challenge, mice are killed by exsanguination from abdominal aorta under urethane (1.6 g/kg, intraperitoneally) anesthesia.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nagashima S, et al. Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1044-55. [Content Brief]

[2]. Chiba Y, et al. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am J Respir Cell Mol Biol. 2009 Nov;41(5):516-24. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5134 mL	12.5672 mL	25.1345 mL	62.8362 mL
	5 mM	0.5027 mL	2.5134 mL	5.0269 mL	12.5672 mL
	10 mM	0.2513 mL	1.2567 mL	2.5134 mL	6.2836 mL
	15 mM	0.1676 mL	0.8378 mL	1.6756 mL	4.1891 mL
	20 mM	0.1257 mL	0.6284 mL	1.2567 mL	3.1418 mL
	25 mM	0.1005 mL	0.5027 mL	1.0054 mL	2.5134 mL
	30 mM	0.0838 mL	0.4189 mL	0.8378 mL	2.0945 mL
	40 mM	0.0628 mL	0.3142 mL	0.6284 mL	1.5709 mL
	50 mM	0.0503 mL	0.2513 mL	0.5027 mL	1.2567 mL
	60 mM	0.0419 mL	0.2095 mL	0.4189 mL	1.0473 mL
	80 mM	0.0314 mL	0.1571 mL	0.3142 mL	0.7855 mL

Keywords

AS1517499

48 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AS1517499

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) AS1517499

Alle STAT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (48)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AS1517499

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) AS1517499

Alle STAT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (48)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AS1517499 Related Classifications

Art. -Nr.: HY-100614